Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. (18)f-dopa
2. 18f-fdopa
3. 2-fluoro-5-hydroxytyrosine
4. 3,4-dihydroxy-6-fluorophenylalanine
5. 3-(2-fluoro-(18)f-4,5-dihydroxyphenyl)-l-alanine
6. 6-(18f)fluoro-l-3,4-dihydroxyphenylalanine
7. 6-(18f)fluoro-l-dopa
8. 6-fluoro-dopa
9. 6-fluorodopa
10. Fluorodopa
11. Fluorodopa F 18
12. Fluorodopa F 18, (18)f-labeled Cpd
13. Fluorodopa F-18
1. Fluorodopa F 18
2. Fluorodopa F18
3. Fluorodopa F-18
4. 92812-82-3
5. 18f-dopa
6. L-6-(18f)fluoro-dopa
7. Fluorine-18-fluoro-l-dopa
8. 18f-l-fluoro-dopa
9. Fdopa F-18
10. Fluorodopa (18f) [inn]
11. Chebi:49166
12. 2c598205qx
13. L-tyrosine, 2-(fluoro-18f)-5-hydroxy-
14. (s)-2-amino-3-(2-(fluoro-18f)-4,5-dihydroxyphenyl)propanoic Acid
15. Fluorodopa F 18 (usan)
16. Fluorodopa F 18 [usan]
17. F-dopa
18. (18f)fdopa
19. 6-(18f)fluoro-l-dopa
20. 2-(fluoro-18f)-l-dopa
21. Unii-2c598205qx
22. Fluorodopa-f-18
23. Fluorodopa F 18 [usan:usp:inn]
24. 2-(fluoro-18f)-5-hydroxy-l-tyrosine
25. Fluorodopa ((18)f)
26. Fluorodopa F18 (tn)
27. Schembl522323
28. Fluorodopa F18 [mi]
29. ((18)f)fdopa
30. 6-((18)f)fluoro-l-dopa
31. Chembl3400972
32. L-6-((18)f)fluoro-dopa
33. Dtxsid60239157
34. Moli000246
35. Moli000965
36. Fluorodopa (18f) [who-dd]
37. Db13848
38. Fluorodopa F-18 [orange Book]
39. 18f-fluoro-dihydroxyphenylalanine
40. Fluorodopa F 18 [usp Impurity]
41. 2-((18)f)fluoro-5-hydroxy-l-tyrosine
42. 2-(fluoro-(18)f)-5-hydroxy-l-tyrosine
43. D04220
44. L-tyrosine, 2-(fluoro-(sup 18)f)-5-hydroxy-
45. 6-((18)f)fluoro-3,4-dihydroxy-l-phenylalanine
46. L-3,4-dihydroxy-6-(18f)fluorophenylalanine
47. 3-(2-fluoro-(18)f-4,5-dihydroxyphenyl)-l-alanine
48. 6-fluoro-(18f)-l-3,4-dihydroxyphenylalanine
49. Q27121509
50. (18f)-6-fluoro-l,3,4, Dihydroxyphenylalanine
51. 3-(2-fluoro-(sup 18)f-4,5-dihydroxyphenyl)-l-alanine
52. (2s)-2-amino-3-(2-(18f)fluoranyl-4,5-dihydroxyphenyl)propanoic Acid
53. (2s)-2-amino-3-[2-((18)f)fluoro-4,5-dihydroxyphenyl]propanoic Acid
| Molecular Weight | 214.18 g/mol |
|---|---|
| Molecular Formula | C9H10FNO4 |
| XLogP3 | -2 |
| Hydrogen Bond Donor Count | 4 |
| Hydrogen Bond Acceptor Count | 6 |
| Rotatable Bond Count | 3 |
| Exact Mass | 214.061920 g/mol |
| Monoisotopic Mass | 214.061920 g/mol |
| Topological Polar Surface Area | 104 Ų |
| Heavy Atom Count | 15 |
| Formal Charge | 0 |
| Complexity | 238 |
| Isotope Atom Count | 1 |
| Defined Atom Stereocenter Count | 1 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Fluorodopa F 18 is indicated for use with positron emission tomography (PET) to visualize dopaminergic nerve terminals in the striatum for the evaluation of adult patients with suspected Parkinsonian syndromes (PS).
V - Various
V09 - Diagnostic radiopharmaceuticals
V09I - Tumour detection
V09IX - Other diagnostic radiopharmaceuticals for tumour detection
V09IX05 - Fluorodopa (18F)
Route of Elimination
Approximately 80% of the administered radioactivity is eliminated in the urine.
Clearance
The agent is cleared from blood and tissue within 24 hours following administration.
Fluorodopa F 18 is decarboxylated by aromatic amino acid decarboxylase (AADC) in the striatum to fluorodopamine F 18. Fluorodopamine F 18 is then further metabolized by monoamine oxidase (MAO) to yield [18F] 6-fluoro-3,4-dihydroxyphenylacetic acid, then subsequently by COMT to yield [18F]6-fluorohomovanillic acid.
The plasma half-life following intravenous administration is approximately 1-3 hours.
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?
